Floatz logo

su011248

Ann Arbor Stage III Hodgkin Lymphoma

OHSU Knight Cancer InstitutePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Ann Arbor Stage III Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
National Cancer Institute (NCI)
Phase 3BB
Calcium folinate pentahydrate
OHSU Knight Cancer Institute
Phase 2BB
Tazemetostat
National Cancer Institute (NCI)
Phase 2B
Idelalisib
OHSU Knight Cancer Institute
Phase 2CCC
Olaparib
OHSU Knight Cancer Institute
Phase 1CC

View all 38 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →